Exemestane: How Kidney and Liver Impairment Affect Drug Exposure

Kidney and liver function can influence how the body handles medicines. For exemestane, sold under the brand name Aromasin, research shows that significant impairment of either organ can increase exposure to the drug.

However, increased exposure does not automatically translate into a proportional increase in clinical effect—or a requirement to reduce the dose.

What Did the Study Investigate?

In a 2004 study published in Cancer Chemotherapy and Pharmacology, Jannuzzo and colleagues examined exemestane pharmacokinetics in postmenopausal women with differing levels of kidney or liver function.

Two separate investigations compared participants with impaired organ function against healthy comparison groups. Each participant received a single oral dose of exemestane, followed by blood and urine sampling. Researchers also monitored vital signs, laboratory results, ECGs and adverse events.

This was a study of drug handling and short-term tolerability, rather than a trial of long-term treatment outcomes.

What Do AUC and Peak Concentration Mean?

The researchers measured several aspects of drug exposure:

MeasurementWhat it describesAUCOverall exposure, calculated from drug concentration over timeCmaxHighest measured drug concentrationApparent oral clearanceAn estimate of drug clearance after oral administration that also depends on bioavailability

A higher AUC means greater overall exposure. It does not necessarily mean the medicine is proportionally more effective.

How Did Liver Impairment Affect Exemestane?

Participants with moderate or severe liver impairment had approximately two- to threefold higher exposure than healthy participants. Peak concentrations also increased, while apparent oral clearance decreased.

In practical terms, the same administered amount produced greater exposure in the impaired groups.

How Did Kidney Impairment Affect Exemestane?

Kidney impairment was also associated with increased overall exposure and reduced apparent oral clearance. Unlike the liver findings, peak concentrations did not change significantly.

The renal-results paragraph in the supplied abstract repeats “hepatic impairment”; in context, that paragraph concerns the kidney-function groups.

These findings demonstrate altered pharmacokinetics, but they do not establish that reduced direct kidney excretion is the sole explanation.

Did the Researchers Identify Safety Concerns?

The investigators reported that the single dose was well tolerated and considered the therapeutic implications of the exposure changes minor.

That conclusion belongs within the study’s boundaries. The groups were small, all participants were postmenopausal women, and each received only one dose. The findings do not establish long-term safety in every patient or validate use in bodybuilding.

What Does Prescribing Information Say?

Pfizer’s US prescribing information acknowledges increased exemestane exposure in moderate or severe kidney or liver impairment. It states that dosage adjustment does not appear necessary, based on the broader clinical experience described in the label.

This distinction matters: a measurable pharmacokinetic change does not always require a different prescribed dose. Treatment decisions consider the medicine’s safety data and clinical context as well as exposure.

Patients should still tell their prescriber about kidney or liver problems and should not change their dose using the study’s exposure ratios.

What Can Readers Conclude?

Significant kidney or liver impairment can increase exemestane exposure. The study’s authors nevertheless considered the clinical implications limited, and US prescribing information does not routinely require adjustment solely for these conditions.

The research does not show that Aromasin is harmless to the kidneys or liver, nor does it establish a dosing strategy for athletes. It answers a narrower question: how existing organ impairment changes the body’s handling of exemestane.